CMS proposes delaying certain Medicaid value-based drug payment requirements
![CMS-rule-proposed-blue-gradient-bkgd](/sites/default/files/styles/900x400/public/2018-08/CMS-rule-proposed-blue-gradient-bkgd.jpg?itok=PL4BvBy2)
The Centers for Medicare & Medicaid Services yesterday proposed delaying Medicaid “best price” and “best price reporting” requirements for state value-based purchasing agreements with drug manufacturers until July 2022. The six-month delay also would apply to a requirement that drug makers include drugs sold in U.S. territories when calculating the best price. The requirements were included in a December 2020 CMS final rule on value-based drug payment. CMS will accept comments on the proposed rule through June 28. The Pharmaceutical Research and Manufacturers of America last week challenged portions of the final rule in federal court.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services today posted the final incentive payment adjustment factors for the fiscal year 2019 Hospital Value-Based…
Perspective
It’s been well established that the health care system is moving from a fee-for-service world to one where payers reward value over volume. This requires care…
Headline
The Centers for Medicare & Medicaid Services today approved for Oklahoma the first state Medicaid plan amendment to allow supplemental rebate agreements…
Headline
The Comprehensive Primary Care Initiative reduced hospitalizations and emergency department visits and improved primary care delivery for beneficiaries, but…
Headline
A new certificate program from the AHA’s Association for the Healthcare Environment will teach health care leaders who purchase or recommend products and…
Headline
The AHA today released a TrendWatch report to help hospital and health system leaders better understand the current landscape of value-based payment models and…